

David Conen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3573161/publications.pdf>

Version: 2024-02-01

174
papers

14,085
citations

71102

41
h-index

24258

110
g-index

179
all docs

179
docs citations

179
times ranked

16532
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac autonomic function and cognitive performance in patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, 111, 60-69.	3.3	4
2	Short-term and Long-term Risk of Stroke in Patients With Perioperative Atrial Fibrillation After Cardiac Surgery: Systematic Review and Meta-analysis. <i>CJC Open</i> , 2022, 4, 85-96.	1.5	17
3	Continuous Noninvasive Remote Automated Blood Pressure Monitoring With Novel Wearable Technology: A Preliminary Validation Study. <i>JMIR MHealth and UHealth</i> , 2022, 10, e24916.	3.7	5
4	Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. <i>Trials</i> , 2022, 23, 101.	1.6	10
5	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. <i>Europace</i> , 2022, , .	1.7	13
6	Silent brain infarcts impact on cognitive function in atrial fibrillation. <i>European Heart Journal</i> , 2022, 43, 2127-2135.	2.2	50
7	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. <i>Circulation</i> , 2022, 145, 392-409.	1.6	65
8	Long-term risk of adverse outcomes according to atrial fibrillation type. <i>Scientific Reports</i> , 2022, 12, 2208.	3.3	5
9	Association between ventricular repolarization parameters and cardiovascular death in patients of the SWISS-AF cohort. <i>International Journal of Cardiology</i> , 2022, , .	1.7	0
10	High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality. <i>New England Journal of Medicine</i> , 2022, 386, 827-836.	27.0	69
11	Elevated Lipoprotein(a) and Risk of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1579-1590.	2.8	42
12	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1434-1441.	1.7	2
13	Use of Anticoagulation Therapy in Patients With Perioperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2022, 4, 840-847.	1.5	3
14	The Admit-AF risk score: A clinical risk score for predicting hospital admissions in patients with atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 624-630.	1.8	3
15	Frailty to predict unplanned hospitalization, stroke, bleeding, and death in atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 42-51.	4.0	33
16	Association of psychosocial factors with all-cause hospitalizations in patients with atrial fibrillation. <i>Clinical Cardiology</i> , 2021, 44, 51-57.	1.8	5
17	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
18	Post Discharge after Surgery Virtual Care with Remote Automated Monitoring Technology (PVC-RAM): protocol for a randomized controlled trial. <i>CMAJ Open</i> , 2021, 9, E142-E148.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation. <i>Cmaj</i> , 2021, 193, E117-E123.	2.0	4
20	The Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) Correlates Inversely with Ischemic Brain Infarcts in Patients with Atrial Fibrillation. <i>Nutrients</i> , 2021, 13, 651.	4.1	7
21	Blood Pressure and Brain Lesions in Patients With Atrial Fibrillation. <i>Hypertension</i> , 2021, 77, 662-671.	2.7	8
22	Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. <i>Europace</i> , 2021, 23, 1200-1210.	1.7	8
23	Biomarkers of Inflammation and Risk of Hospitalization for Heart Failure in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e019168.	3.7	12
24	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 512-519.	0.7	7
25	Association Between Perioperative Atrial Fibrillation and Long-term Risks of Stroke and Death in Noncardiac Surgery: Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, 666-674.	1.5	7
26	Association of Heart Rate Variability With Silent Brain Infarcts in Patients With Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 684461.	2.4	2
27	New-Onset Perioperative Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Risk of Adverse Events: An Analysis From the CORONARY Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020426.	3.7	13
28	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. <i>CJC Open</i> , 2021, 3, 1482-1489.	1.5	9
29	LVS-CHARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017735.	3.7	4
30	Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022222.	3.7	38
31	Subclinical thyroid function and cardiovascular events in patients with atrial fibrillation. <i>European Journal of Endocrinology</i> , 2021, 185, 375-385.	3.7	8
32	Biomarkers, Clinical Variables, and the CHA2DS2-VASc Score to Detect Silent Brain Infarcts in Atrial Fibrillation Patients. <i>Journal of Stroke</i> , 2021, 23, 449-452.	3.2	3
33	Alcohol consumption, atrial fibrillation, and cardiovascular disease: finding the right balance. <i>European Heart Journal</i> , 2021, 42, 1178-1179.	2.2	9
34	Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss-CAF Study. <i>Journal of the American Heart Association</i> , 2021, 10, e021800.	3.7	16
35	Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. <i>European Heart Journal</i> , 2020, 41, 645-651.	2.2	48
36	C-reactive protein for prediction of atrial fibrillation recurrence after catheter ablation. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 427.	1.7	16

#	ARTICLE	IF	CITATIONS
37	A factor score reflecting cognitive functioning in patients from the Swiss Atrial Fibrillation Cohort Study (Swiss-AF). PLoS ONE, 2020, 15, e0240167.	2.5	5
38	Long-term Results After Drug-eluting Versus Bare-metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial. Journal of the American Heart Association, 2020, 9, e017434.	3.7	7
39	The Value of Large Randomized Trials of Two Active Interventions to Define the Optimal Treatment in Patients With Acute Coronary Syndrome. Annals of Internal Medicine, 2020, 173, 494-495.	3.9	0
40	Can you feel the beat? How to define reference ranges for ambulatory heart rhythm monitoring. Heart, 2020, 106, 1708-1709.	2.9	2
41	Heart Rate Variability Triangular Index as a Predictor of Cardiovascular Mortality in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e016075.	3.7	38
42	Preoperative levels of natriuretic peptides and the incidence of postoperative atrial fibrillation after noncardiac surgery: a prospective cohort study. Cmaj, 2020, 192, E1715-E1722.	2.0	5
43	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal, 2020, 41, 3437-3447.	2.2	78
44	Response to "Electrocardiographic sexual differences in patients with atrial fibrillation". International Journal of Cardiology, 2020, 308, 50-51.	1.7	1
45	Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction. Nature Communications, 2020, 11, 2542.	12.8	59
46	Canakinumab After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008197.	4.8	12
47	Symptoms and quality of life in patients with coexistent atrial fibrillation and atrial flutter. IJC Heart and Vasculature, 2020, 29, 100556.	1.1	4
48	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. Europace, 2020, 22, 870-877.	1.7	13
49	Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007676.	4.8	30
50	Aldosterone-to-renin ratio and blood pressure in young adults from the general population. American Heart Journal, 2020, 222, 199-207.	2.7	4
51	Change in Atrial Fibrillation Burden over Time in Patients with Nonpermanent Atrial Fibrillation. Cardiology Research and Practice, 2020, 2020, 1-7.	1.1	3
52	Associations of symptoms and quality of life with outcomes in patients with atrial fibrillation. Heart, 2020, 106, 1847-1852.	2.9	8
53	Association of the CHA2D(S2)-VASc Score and Its Components With Overt and Silent Ischemic Brain Lesions in Patients With Atrial Fibrillation. Frontiers in Neurology, 2020, 11, 609234.	2.4	2
54	Sex-related electrocardiographic differences in patients with different types of atrial fibrillation: Results from the SWISS-AF study. International Journal of Cardiology, 2020, 307, 63-70.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
56	Atrial fibrillation for internists: current practice. Swiss Medical Weekly, 2020, 150, w20196.	1.6	0
57	The heart-brain connection: further establishing the relationship between atrial fibrillation and dementia?. European Heart Journal, 2019, 40, 2324-2326.	2.2	10
58	Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.9	1
59	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PLoS ONE, 2019, 14, e0210821.	2.5	5
60	Risk of Hospital Admissions in Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2019, 35, 1332-1343.	1.7	37
61	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 989-999.	2.8	148
62	Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis. Heart, 2019, 105, 1884-1891.	2.9	40
63	Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC: Clinical Electrophysiology, 2019, 5, 1406-1414.	3.2	9
64	Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation. PLoS ONE, 2019, 14, e0226730.	2.5	30
65	Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2019, 322, 2292.	7.4	85
66	Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis. Heart Rhythm, 2019, 16, 502-510.	0.7	46
67	Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation. ESC Heart Failure, 2019, 6, 182-193.	3.1	18
68	Association of 24-Hour Blood Pressure With Urinary Sodium Excretion in Healthy Adults. American Journal of Hypertension, 2018, 31, 784-791.	2.0	9
69	Relationships of kidney injury molecule-1 with renal function and cardiovascular risk factors in the general population. Clinica Chimica Acta, 2018, 478, 13-17.	1.1	7
70	Colchicine for Prevention of Perioperative Atrial Fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study. European Journal of Cardio-thoracic Surgery, 2018, 53, 945-951.	1.4	21
71	Fibroblast growth factor 23 and renal function among young and healthy individuals. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1483-1489.	2.3	2
72	Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults. Journal of Hypertension, 2018, 36, 1548-1554.	0.5	30

#	ARTICLE	IF	CITATIONS
73	Strokeâ€prevention strategies in North American patients with atrial fibrillation: The GLORIAâ€AF registry program. <i>Clinical Cardiology</i> , 2018, 41, 744-751.	1.8	19
74	Left atrial anatomy, atrial fibrillation burden, and P-wave durationâ€™relationships and predictors for single-procedure success after pulmonary vein isolation. <i>Europace</i> , 2018, 20, 271-278.	1.7	26
75	Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries. <i>Europace</i> , 2018, 20, 963-970.	1.7	54
76	Bariatric surgery among patients with heart failure: a systematic review and meta-analysis. <i>Open Heart</i> , 2018, 5, e000910.	2.3	29
77	Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. <i>Nature Genetics</i> , 2018, 50, 1412-1425.	21.4	924
78	Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) followâ€™up cohort study. <i>Clinical Cardiology</i> , 2018, 41, 1273-1280.	1.8	13
79	Healthy lifestyle and prevention of atrial fibrillation: Weighty matters. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1371-1373.	1.8	2
80	Progression of Device-Detected Subclinical Atrial Fibrillation and the Riskâ€™of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	2.8	91
81	Risk factors for heart failure hospitalizations among patients with atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191736.	2.5	9
82	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018, 50, 1225-1233.	21.4	552
83	Relationship between QRS duration and incident atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 266, 84-88.	1.7	19
84	QTc interval, cardiovascular events and mortality in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 252, 101-105.	1.7	14
85	Prevalence and predictors of atrial fibrillation type among individuals with recent onset of atrial fibrillation. <i>Swiss Medical Weekly</i> , 2018, 148, w14652.	1.6	11
86	Number of Pregnancies and Atrial Fibrillation Risk. <i>Circulation</i> , 2017, 135, 622-624.	1.6	27
87	Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED): an open-label randomised controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 282-290.	10.2	208
88	Healthy Lifestyle and Blood Pressure Variability in Young Adults. <i>American Journal of Hypertension</i> , 2017, 30, 690-699.	2.0	28
89	Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. <i>Nature Genetics</i> , 2017, 49, 946-952.	21.4	279
90	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453

#	ARTICLE	IF	CITATIONS
91	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolic in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	2.7	258
92	Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2017, 5, 552-560.	4.1	58
93	Risk factors for premature ventricular contractions in young and healthy adults. <i>Heart</i> , 2017, 103, 702-707.	2.9	50
94	Conventional versus 3D Echocardiography to Predict Arrhythmia Recurrence After Atrial Fibrillation Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 651-658.	1.7	11
95	Atrial Fibrillation and Cancer—Validation in the Real World—Reply. <i>JAMA Cardiology</i> , 2017, 2, 344.	6.1	1
96	Relationships of Measured and Genetically Determined Height With the Cardiac Conduction System in Healthy Adults. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	19
97	Prospective Assessment of Sex-Related Differences in Symptom Status and Health Perception Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	44
98	Healthy lifestyle and glucagon-like peptide-1 in young and healthy adults: A population-based study. <i>Preventive Medicine</i> , 2017, 101, 72-76.	3.4	1
99	Pitcher perfect: arrhythmia monitoring at the Munich Oktoberfest. <i>European Heart Journal</i> , 2017, 38, 2107-2109.	2.2	13
100	Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents—A clinical and health-economic evaluation. <i>Cardiovascular Therapeutics</i> , 2017, 35, 19-25.	2.5	18
101	Heart rate, heart rate variability and inflammatory biomarkers among young and healthy adults. <i>Annals of Medicine</i> , 2017, 49, 32-41.	3.8	47
102	Factors independently associated with cardiac troponin I levels in young and healthy adults from the general population. <i>Clinical Research in Cardiology</i> , 2017, 106, 96-104.	3.3	21
103	Use of acoustic cardiography immediately following electrical cardioversion to predict relapse of atrial fibrillation. <i>Journal of Atrial Fibrillation</i> , 2017, 10, 1527.	0.5	4
104	Associations of sodium, potassium and protein intake with blood pressure and hypertension in Switzerland. <i>Swiss Medical Weekly</i> , 2017, 147, w14411.	1.6	18
105	Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. <i>Swiss Medical Weekly</i> , 2017, 147, w14467.	1.6	46
106	Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation—a prospective cohort study. <i>Swiss Medical Weekly</i> , 2017, 147, w14410.	1.6	9
107	Determinants of Left Atrial Volume in Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2016, 11, e0164145.	2.5	5
108	The interrelationships of birthweight, inflammation and body composition in healthy adults. <i>European Journal of Clinical Investigation</i> , 2016, 46, 342-348.	3.4	9

#	ARTICLE	IF	CITATIONS
109	Smart detection of atrial fibrillation. <i>Europace</i> , 2016, 19, euw125.	1.7	79
110	High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. <i>Open Heart</i> , 2016, 3, e000515.	2.3	38
111	Relationship of N-Terminal fragment of Pro-B-Type Natriuretic Peptide and copeptin with erythrocytes-related parameters: A population-based study. <i>Clinical Biochemistry</i> , 2016, 49, 651-656.	1.9	2
112	Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 389.	6.1	150
113	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e33.	1.5	0
114	Relationships of iron metabolism with insulin resistance and glucose levels in young and healthy adults. <i>European Journal of Internal Medicine</i> , 2016, 32, 31-37.	2.2	24
115	Heart Rate Variability and Sleep-Related Breathing Disorders in the General Population. <i>American Journal of Cardiology</i> , 2016, 118, 912-917.	1.6	25
116	Relationships of electrocardiographic parameters with ambulatory hypertension in young and healthy adults. <i>International Journal of Cardiology</i> , 2016, 202, 300-304.	1.7	5
117	Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators. <i>Europace</i> , 2016, 18, 1194-1202.	1.7	30
118	Healthy lifestyle and heart rate variability in young adults. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1037-1044.	1.8	34
119	Whole Blood Gene Expression Differentiates between Atrial Fibrillation and Sinus Rhythm after Cardioversion. <i>PLoS ONE</i> , 2016, 11, e0157550.	2.5	11
120	Gender Differences in Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-Defibrillators: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0162756.	2.5	26
121	Prevalence and determinants of chronic kidney disease in the Swiss population. <i>Swiss Medical Weekly</i> , 2016, 146, w14313.	1.6	11
122	Plasma levels of glucagon-like peptide 1 and markers of obesity among young and healthy adults. <i>Clinical Endocrinology</i> , 2015, 83, 636-642.	2.4	12
123	Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents. <i>Circulation</i> , 2015, 131, 74-81.	1.6	87
124	Effects of Sinus Rhythm Maintenance on Left Heart Function After Electrical Cardioversion of Atrial Fibrillation: Implications for Tachycardia-Induced Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2015, 31, 36-43.	1.7	28
125	Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis. <i>European Heart Journal</i> , 2015, 36, 897-898.	2.2	11
126	Plasma endothelin-1 and cardiovascular risk among young and healthy adults. <i>Atherosclerosis</i> , 2015, 239, 186-191.	0.8	23

#	ARTICLE	IF	CITATIONS
127	Glucagon-Like Peptide-1 and Blood Pressure in Young and Healthy Adults from the General Population. <i>Hypertension</i> , 2015, 65, 306-312.	2.7	17
128	Misconceptions and Facts About Atrial Fibrillation. <i>American Journal of Medicine</i> , 2015, 128, 938-942.	1.5	9
129	Edoxaban and amiodarone: interactions on multiple levels. <i>European Heart Journal</i> , 2015, 36, 2210-2211.	2.2	3
130	Relationship Between High-Sensitivity Cardiac Troponin I and Blood Pressure Among Young and Healthy Adults. <i>American Journal of Hypertension</i> , 2015, 28, 789-796.	2.0	34
131	Paradoxical Association of Lipoprotein Measures With Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 612-619.	4.8	75
132	Predisposing Factors Associated With Development of Persistent Compared With Paroxysmal Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2014, 3, e000916.	3.7	69
133	Serum bilirubin levels and risk of prediabetes in young and healthy adults. <i>International Journal of Cardiology</i> , 2014, 171, e24-e25.	1.7	6
134	Long-term comparison of cryoballoon and radiofrequency ablation of paroxysmal atrial fibrillation: A propensity score matched analysis. <i>International Journal of Cardiology</i> , 2014, 176, 645-650.	1.7	37
135	Age-Specific Differences Between Conventional and Ambulatory Daytime Blood Pressure Values. <i>Hypertension</i> , 2014, 64, 1073-1079.	2.7	78
136	Alcohol Consumption and Risk of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 290-292.	2.8	22
137	Seasonality of cardiovascular risk factors: an analysis including over 230,000 participants in 15 countries. <i>Heart</i> , 2014, 100, 1517-1523.	2.9	113
138	Association of smoking and nicotine dependence with pre-diabetes in young and healthy adults. <i>Swiss Medical Weekly</i> , 2014, 144, w14019.	1.6	14
139	Atrial fibrillation: A moving target. <i>Swiss Medical Weekly</i> , 2014, 144, w14078.	1.6	2
140	Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. <i>International Journal of Cardiology</i> , 2013, 168, 1894-1899.	1.7	32
141	Factors associated with 24-hour urinary volume: the Swiss salt survey. <i>BMC Nephrology</i> , 2013, 14, 246.	1.8	23
142	Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP). <i>Swiss Medical Weekly</i> , 2013, 143, w13728.	1.6	30
143	Antihypertensive treatment – navigating between cost, compliance and complications. <i>Swiss Medical Weekly</i> , 2013, 143, w13857.	1.6	1
144	Premature Atrial Contractions in the General Population. <i>Circulation</i> , 2012, 126, 2302-2308.	1.6	135

#	ARTICLE	IF	CITATIONS
145	How Does Alcohol Intake Relate to the Risk of Atrial Fibrillation?. Journal of Atrial Fibrillation, 2012, 5, 433.	0.5	0
146	Smoking, Smoking Cessation, and Risk for Symptomatic Peripheral Artery Disease in Women. Annals of Internal Medicine, 2011, 154, 719.	3.9	79
147	Risk of Death and Cardiovascular Events in Initially Healthy Women With New-Onset Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2011, 305, 2080.	7.4	308
148	Sex Differences in Atrial Fibrillation and Its Complications. Current Cardiovascular Risk Reports, 2010, 4, 237-243.	2.0	1
149	Response to Letter Regarding Article, "Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women": Circulation, 2010, 121, .	1.6	2
150	Caffeine consumption and incident atrial fibrillation in women. American Journal of Clinical Nutrition, 2010, 92, 509-514.	4.7	85
151	Use of A Mendelian Randomization Approach to Assess the Causal Relation of γ -Glutamyltransferase with Blood Pressure and Serum Insulin Levels. American Journal of Epidemiology, 2010, 172, 1431-1441.	3.4	31
152	Birth Weight Is a Significant Risk Factor for Incident Atrial Fibrillation. Circulation, 2010, 122, 764-770.	1.6	70
153	A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. European Heart Journal, 2010, 31, 1730-1736.	2.2	140
154	The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 55, 2319-2327.	2.8	419
155	Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. Swiss Medical Weekly, 2010, 140, 202-8.	1.6	10
156	Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women. Circulation, 2009, 119, 2146-2152.	1.6	285
157	Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. European Heart Journal, 2009, 30, 1378-1384.	2.2	75
158	Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study. Journal of Hypertension, 2009, 27, 476-483.	0.5	40
159	Differential Citation Rates of Major Cardiovascular Clinical Trials According to Source of Funding. Circulation, 2008, 118, 1321-1327.	1.6	27
160	Alcohol Consumption and Risk of Incident Atrial Fibrillation in Women. JAMA - Journal of the American Medical Association, 2008, 300, 2489.	7.4	173
161	Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. Journal of Hypertension, 2008, 26, 1290-1299.	0.5	151
162	Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study. Journal of Hypertension, 2008, 26, 1780-1786.	0.5	37

#	ARTICLE	IF	CITATIONS
163	Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2007, 335, 432.	2.3	94
164	Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension. <i>Hypertension</i> , 2007, 50, 1114-1119.	2.7	33
165	Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. <i>Biomarkers in Medicine</i> , 2007, 1, 229-241.	1.4	14
166	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. <i>European Heart Journal</i> , 2007, 28, 2937-2943.	2.2	153
167	Amiodarone-Induced Thyrotoxicosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2350-2355.	2.8	71
168	C-Reactive Protein and B-Type Natriuretic Peptides in Never-Treated White Coat Hypertensives. <i>Hypertension Research</i> , 2006, 29, 411-415.	2.7	13
169	Routine Blood Pressure Measurements Do Not Predict Adverse Events in Hospitalized Patients. <i>American Journal of Medicine</i> , 2006, 119, 70.e17-70.e22.	1.5	9
170	Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2006, 110, 237-241.	1.7	21
171	Value of Repeated Cardiac Magnetic Resonance Imaging in Patients with Suspected Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2006, 8, 361-366.	3.3	9
172	High prevalence of newly detected hypertension in hospitalized patients: the value of in-hospital 24-h blood pressure measurement. <i>Journal of Hypertension</i> , 2006, 24, 301-306.	0.5	24
173	Usefulness of B-Type Natriuretic Peptide and C-Reactive Protein in Predicting the Presence or Absence of Left Ventricular Hypertrophy in Patients With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2006, 97, 249-252.	1.6	50
174	Montelukast and Churg-Strauss syndrome. <i>Swiss Medical Weekly</i> , 2004, 134, 377-80.	1.6	9